Currently, several large randomized studies showed that PD-1/PD-L1 inhibitors in combination with neoadjuvant chemotherapy for advanced TNBC breast cancer were associated with an important clinical benefit [31, 32]. This evidence concerns the gene CD274 and breast carcinoma.